West Pharmaceutical Services WST · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
413.09
+3.32%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $29.07bn
- Last close × shares
- Volume
- 555.2k
- Shares, 9 Nov 2026
- Price to earnings
- 60.2
- Dividend yield
- 0.22%
About West Pharmaceutical Services
From its filings with the US Securities and Exchange Commission
West Pharmaceutical Services is based in Exton, Pennsylvania and is incorporated in Pennsylvania. Its shares trade on NYSE under the ticker WST. It is a member of the S&P 500. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $3.07bn and net income of $493.7m. At that date it held total assets of $4.27bn and shareholders' equity of $3.18bn. By business, Proprietary Products brought in 81.1% of revenue, followed by Contract-Manufactured Products at 18.9%. By region, United States accounted for 43.3%, followed by Other European countries at 14.7% and Germany at 12.4%.
We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies in the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.
Our business operations are organized into two global business segments, Proprietary Products and Contract-Manufactured Products.
Our Proprietary Products reportable segment offers elastomers & primary containment, drug delivery devices, integrated systems, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. Our packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability with active drug products, while also supporting operational efficiency for customers.
Quoted from its 10-K, filed 17 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2025
- Proprietary Products $2.49bn · 81.1%
- Contract-Manufactured Products $582.0m · 18.9%
Latest on West Pharmaceutical Services
Our reporting
Next results
Due on 11 Feb 2027. Analysts expect earnings of 2.27 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is West Pharmaceutical Services's ticker?
West Pharmaceutical Services trades as WST on its US listing, under ISIN US9553061055.
What was West Pharmaceutical Services's last closing price?
413.09 on 9 Nov 2026. The figure is in USD and is never converted.
When does West Pharmaceutical Services next report results?
Results are expected on 11 Feb 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.